TheBrief.Health
Adagio Medical’s FDA submission for its ultra-low temperature ventricular ablation system could expand treatment options for drug-refractory ventricular tachycardia, offering deeper lesion creation, fewer ICD shocks, reduced antiarrhythmic dependence, and improved procedural outcomes.
518 episodes
Comments
0Be the first to comment
Sign up now and become a member of the TheBrief.Health community!